“The current condition has exposed some structural weaknesses in the EU’s medicines offer chain and also a high dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides said. She proposed that offer chain concerns be tackled in an EU pharmaceutical tactic expected to be launched by the top of your 12 months.Automation a